diabetestalk.net

Medtronic Insulin Pump Canada

Insulin Pump Options For Current Animas Customers

Insulin Pump Options For Current Animas Customers

Johnson and Johnson announced on October 5, 2017 that it is exiting the insulin pump business and will no longer make and sell the Animas Vibe and OneTouch Ping insulin pumps in the U.S. and Canada. Diabetes Daily shared what Animas pump users need to know including information on who is affected and what to do if you currently have a warranty or are out of warranty. If this affects you and you are now looking into insulin pump options, there are replacement programs from Medtronic, Tandem, and Insulet. Animas has partnered with Medtronic for this transition, but insulin pump users should realize that they do have a choice in which insulin pump they use and they should think about the features of each pump, how each pump may best aid in diabetes management, and which of the programs offered by Medtronic, Tandem, and Insulet may benefit them. People with diabetes should also contact the insulin pump company they ultimately choose as a replacement to make sure they understand all the fine print as well as speak with their insurance company to determine coverage of supplies, etc. Medtronic Medtronic’s program is available to current Animas customers. Options differ depending on when the Animas pump warranty expires. Highlights: MiniMed 670G is available for U.S. customers MiniMed 630G is available for Canadian customers Highlights for warranties expiring on or after September 30, 2019: You will transition to the MiniMed 630G insulin pump This option will be available beginning May of 2018 This will be at no cost at that time To switch to a Medtronic pump before May 2018 or the warranty expiration, you can use an in-warranty upgrade program called Switch2System Visit Medtronic’s page for Animas customers for more information. Medtronic currently has three models availab Continue reading >>

First Artificial Pancreas Approved In U.s. For Diabetes: When Will Canadians Get It?

First Artificial Pancreas Approved In U.s. For Diabetes: When Will Canadians Get It?

First artificial pancreas approved in U.S. for diabetes: When will Canadians get it? Millions of Canadians with diabetes need to test themselves several times a day. There is always hope: Lethbridge man walks 100km to raise awareness for diabetes There are two types of diabetes: type 1 and type 2. In the case of type 1, the pancreasdoesnt produce any insulin to regulate blood sugar. In type 2, either the pancreas doesnt produce enough or the body cant utilize what is produced efficiently. Those with diabetesneed to carefully regulate their blood sugar and, if they dont, it could be fatal. In order to monitor their blood sugar, those with diabetes need totest and then administer the correct dose of insulin. Some dont inject themselves with syringes, but rather wear an insulin pump that delivers the life-saving medicine into the system continuously. When they eat, they need to give themselves an added dose, called a bolus, to cover off the carbs they consume. In Canada, these pumps are funded for patients in every province. Jordan DePape removes his insulin pump before practice. For years companies around the world have been developing a system whereblood glucose levels are continuously monitored, reducing the highs and lows patients may suffer throughout the day. Dubbed the artificial pancreas, this device would further ensure the safety people with diabetes. On Wednesday, theFDA approved Medtronics MiniMed 670G , the first artificial pancreas. This device will mean peace of mind, in knowing a person will be in normal blood sugar range a great majority of the time, said Derek Rapp, chief executive officer of the Juvenile DiabetesResearch Foundation (JDRF), which has spent $116 million on research in the artificial pancreas field. It is a major news event that a system o Continue reading >>

Medtronic Announces Health Canada Licence Of The Minimed™ 630g System With New User-friendly Insulin Pump Design And Smartguard™ Technology

Medtronic Announces Health Canada Licence Of The Minimed™ 630g System With New User-friendly Insulin Pump Design And Smartguard™ Technology

After interviewing more than 1,000 people with diabetes and testing user-experience, the enhanced features of the MiniMed 630G system were finalized to take into account what matters most to those with diabetes. This collaborative process with the patient community resulted in a new, user-friendly pump design that is waterproof[i] and features a high-definition, full-colour screen that supports easy navigation and enables increased customization with more intuitive menus. “We are excited to announce the launch of the MiniMed 630G system for Canadians living with diabetes. This latest innovation is a step towards Medtronic’s vision of transforming diabetes care and our commitment to providing improved outcomes and an improved user experience for our customers,” said Laura Cameron, Director of Diabetes & Consumer Care in Canada. The MiniMed 630G system combines its proprietary SmartGuard technology with a brand new user-friendly design. The new pump platform fully integrates continuous glucose monitoring (CGM) and SmartGuard technology, which is designed to trigger an alarm when the CGM sensor glucose level reaches a preset low limit and suspends insulin delivery if the user is unresponsive to the alarm. SmartGuard technology is the only feature available in Canada that takes action against lows[i] and is the only system proven to reduce the frequency of nighttime low episodes[ii] by a third.2,[iii] Data from the ASPIRE In-Home Study published in the New England Journal of Medicine2 demonstrated that SmartGuard technology not only reduces the number of low events2 per week by 30 percent but also shortens the length/intensity of those events at night by 37.5 % without increasing A1C (a measure of average blood sugar levels over three months).4 These results were vali Continue reading >>

Tandem In Canada - Diabetes Technology - Tudiabetes Forum

Tandem In Canada - Diabetes Technology - Tudiabetes Forum

Just curious if anyone has heard anything about Tandem in Canada? Like most Animas users having to choose Medtronic, Omnipotent, would love. 3rd option. I am very much considering the Tandem if it ever comes north of the 49th parallel. Funny you should say. SiggyB. A member of the forum just informed me that it should be coming to Canada this year. I wonder just what an omnipotent Omnipod could treat besides diabetes! Sorry, I couldnt resist. Sometimes autocorrect has a sense of humor! Yes, it would be nice to have more pump choices. Maybe Tandem will be just what youre looking for. Good luck with selecting your next pump. I am an Animas vibe user and was also thinking of a Tandem pump when it comes to Canada, but after I thought and read about the medtronic company being the most advanced in the technology Im thinking I should be able to get the most innovative pump and not have to worry so much about the company leaving the insulin pump business. I am very excited with the Growth of Tandem. Each quarter as it releases its corporate earnings statement, in my opinion, this is a growing company with a very bright future. If a much larger corporation is more comfortable for you then certainly Medtronic may fit your criteria. However as Johnson & Johnson (ie - Animas) has so clearly demonstrated, the size along of a company may not necessarily indicate their future intentions. That being said, there is absolutely no indication of Medtronic leaving the pump market. Everybody must decide for themselves what is in their own best interest. Yes, they are. I received a message from them stating that I could be added to their email database that would keep me updated on their move to Canada. Really? This is great news. I have been using a medtronic pump for many years, I am very Continue reading >>

Insulin Pump Rundown

Insulin Pump Rundown

Choosing an insulin pump doesn’t have to be an overwhelming process. Should you go with a more traditional pump where you can monitor your insulin levels directly? Are you looking for a model that works with a BGM monitor and allows you to administer insulin via a remote? Maybe you need a pump that offers integration with a CGM system. What about size? Color? To use tubes or not to use tubes? Presenting the options so you can find out what pump best fits your lifestyle is our goal. So, with several models on the market, let us help you sort through the choices by taking a look at what’s available and breaking down the various features of each. We’ve separated the pumps into four categories: pumps that incorporate or work with a Blood Glucose Monitor (BGM) and offer Continuous Glucose Monitoring (CGM), pumps with just CGM capability, pumps with just a BGM, and standalone pumps that don’t work with a BGM or offer CGM. Hybrid Closed-Loop System The 670 G system is the newest member to the Medtronic pump family and the first hybrid closed-loop system. In other ways, it is a like a “basal modulator” where you have to still bolus but it predicts your basal rate. Every 5 minutes, the auto-mode option (hybrid closed-loop) automatically adjusts basal insulin delivery based on your sugar levels to keep you range. It is excellent at catching lows because it stops your insulin dosage 30 minutes before you reach your pre-selected low limits, then it will automatically restart insulin when your levels recover. Possible concerns: excessive alerts and extended menu that needs clearing. Only approved for ages 14+ because it has a total daily dose requirement of at least 8 units a day. Feeling of loss of control of management with closed-loop system. Pumps with BGM and CGM ca Continue reading >>

Canadas First Medtronic Diabetes Resource Centre Opens In Surrey

Canadas First Medtronic Diabetes Resource Centre Opens In Surrey

From left, Rebecca Merriman (Medtronic), Melissa Louis (Medtronic), Shelley Blonheim (Insulin Pump User), Laura Cameron (Medtronic), Linda Hepner (Surrey Mayor), Neil Fraser (Medtronic) cut the ribbon to officially open a new Medtronic diabetes resource centre in Surrey. (Submitted photo) Canadas first Medtronic diabetes resource centre opens in Surrey Fraser Health says Surrey and Abbotsford have the largest proportion of diabetics in the region SURREY Canadas first Medtronic Resource Centre for patients with diabetes held its grand opening in Surrey this Wednesday (June 14). Located on the main floor of the City Centre 1 building across the street from Surrey Memorial Hospital, the new centre will serve as a one-stop shop for those with diabetes. Its intended to be able to provide support in between clinic visits, explained Laura Cameron director of Medtronic Canadas Diabetes Group. To allow them to better utilize their technology so that they can have better support in managing their diabetes. We hope it will provide additional support to the clinics who will be doing some of the less-basic things with them. Well take care of some of the stuff in between. The goal, she noted, is to elevate their ability to manage their disease and as a result, have better outcomes and fewer complications, thus, improving lives. The new centre will offer insulin pump classes, lessons on CGM (continuous glucose monitoring) and educate patients on carb counting and best travel practices. The centre, within the Innovation Boulevard health tech district , will also provide networking opportunities and one-on-one time with certified insulin pump trainers. Cameron said Surrey was chosen as the location for their centre because of the high prevalence of diabetes in the city, and all of Fras Continue reading >>

Medtronic Warns Of 640g Pump Software Problem

Medtronic Warns Of 640g Pump Software Problem

The pump, which is sold internationally, could fail to charge because of it. sponsor A software problem has been detected in some Medtronic 640G pumps sold in international markets. However, that problem should not affect Medtronic pump users in the U.S. or Canada, as the 640G has not been released in these two countries. In mid-February, some members of the diabetes community began sharing notices from Medtronic of a software problem that may prevent the internal battery of the 640G pump from charging. The notice states that if this problem occurs, a screen will appear with the following message: “Power error detected – 00:00 – 25. Delivery stopped. Record your settings by uploading to CareLink or write your settings on paper. See User Guide.” If users see this alarm, they should contact Medtronic’s Helpline immediately, and someone will assist them in troubleshooting or in ordering a replacement pump. Read “Flaw Detected in Medtronic MiniMed 640G.” sponsor Insulin Nation has been able to find this notice posted in Australia, New Zealand, and Denmark. Customers in other countries may be affected, as well. Medtronic spokeswoman Janet Kim says Medtronic pump users in the U.S. and Canada should not be impacted by this software error, and that those who were affected should already have received notice of the problem. There have been no reports of adverse effects connected to this software problem, Kim said. However, the notice said the error could interrupt insulin delivery, so it should be taken seriously. Read about the FDA approval for the Medtronic 670G. Medtronic elected not to release the 640G in the U.S. and Canada, instead releasing a similar-looking pump that lacked the 640G’s predictive technology (the 630G) and a partially automated insulin pump Continue reading >>

Introducing Convenient Mobile Access To Your Pump And Cgm Data With Minimed Connect

Introducing Convenient Mobile Access To Your Pump And Cgm Data With Minimed Connect

Home Innovation Introducing Convenient Mobile Access To Your Pump And CGM Data With MiniMed Connect Introducing Convenient Mobile Access To Your Pump And CGM Data With MiniMed Connect Posted by Editorial Team On June 4, 2015 In Innovation Today were sharing some great news for people with diabetes, and their care partners and healthcare teams: weve receive FDA clearance of MiniMed Connect! This is the first product to allow people with diabetes to discreetly and conveniently view their insulin pump and CGM data on a smartphone. MiniMed Connect also provides remote monitoring and text notifications for loved ones and more convenient access to more comprehensive data for healthcare teams. Many of you whether youre a person with diabetes, a d-mom, d-dad or other care partner have told us how important it is for you to have remote access and notifications to your diabetes data. This is why were so thrilled to share this news with you today. Designed to provide a mobile connection to your critical diabetes information, MiniMed Connect is compatible with the MiniMed 530G system and MiniMed Revel system. It consists of three parts: A small uploader which easily fits on a keychain or in a pocket A smartphone app for the person with diabetes A web display on desktop or mobile devices for care partners A mobile phone app that shows important insulin pump and CGM information, including: Current sensor glucose reading with high and low limits, shown on a graph (3, 6, 12, and 24-hour views) Real-time sensor glucose values through a new Connect tab in CareLink , which can be accessed from most smartphones, tablets, or computers at any time (as long as they have Internet connectivity) Preset text notifications delivered to your phone when the person with diabetes sensor glucose value Continue reading >>

Comparison Of Pumps

Comparison Of Pumps

Looking for a simple comparison of the insulin pumps currently available in Canada? Confused by technical terms and unfamiliar features? We’ve cut to the chase here, highlighting the features most important to real pump users and their families. (Like us!) For a more detailed explanation of the technical terms as well as a distinguishing between similar and unique features, please see Pump Model Similarities, Unique to Animas Pump, Unique to Medtronic Pump and Unique to Omnipod Pump. The following insulin pumps are currently licensed for distribution in Canada (as of October, 2017): (This article contains affiliate links.) Medtronic Minimed® 630G Omnipod® (by Insulet) Please note that Animas has discontinued the sale of insulin pumps in North America as of October, 2017. They will continue to provide support and sell pump supplies into 2019. *Accu-Chek Animas Ping/Vibe Medtronic Minimed 630G Omnipod ABOUT FORM: N/A The Accu-Chek Spirit Combo insulin pump previously available in Canada has not been distributed since 2016; however, Accu-Chek infusion sets are still available, allowing for a greater range of options for insulin pump users. Is the insulin pump Tubing-Free? No No Yes Is the pump Waterproof? Or Water-Resistant? Waterproof IPX8 Rating (pump guaranteed for submersion of up to 3.6m for 24 hours) Waterproof IPX8 Rating (pump guaranteed for submersion of up to 3.6m for 24 hours) Waterproof IPX8 Rating (pump guaranteed for submersion of up to 3.6m for 24 hours) ABOUT CGM: Does the pump have an integrated Continuous Glucose Monitor (CGM)? Yes (Vibe) No (Ping) Yes No For those with an integrated CGM, does it include a Low-Glucose Suspend feature? No Yes n/a Is the most recent glucose reading displayed on the home screen? Yes (Vibe) Yes n/a ABOUT BASAL INSULIN: Ca Continue reading >>

Medtronic Secures Health Canada License For Minimed 630g System

Medtronic Secures Health Canada License For Minimed 630g System

Medtronic secures Health Canada license for MiniMed 630G system Medtronic (NYSE: MDT ) subsidiary Medtronic Canada said today that it landed a license with Health Canada for its MiniMed 630G insulin pump system for patients with diabetes mellitus. The Fridley, Minn.-based company said it interviewed more than 1,000 diabetes patients to better understand the features they lookfor in an insulin pump. The final product has a user-friendly pump that is waterproof in up to12 feet of water for a maximum of 24 hours and features a high-definition screen. The 630G system integrates continuous glucose monitoring and the companys SmartGuard tech, which triggers an alarm when the sensor reaches a preset low limit. If the user in unresponsive to the alarm, the device will suspend insulin delivery. The SmartGuard features are the 1st of its kind in Canada, according to Medtronic. We are excited to announce the launch of the MiniMed 630G system for Canadians living with diabetes, director of diabetes & consumer care, Laura Cameron, said in prepared remarks. This latest innovation is a step towards Medtronics vision of transforming diabetes care and our commitment to providing improved outcomes and an improved user experience for our customers. The devicewill be commercially available in Canada in early 2017. Medtronic announced the US launch of the MiniMed 630G in August and recently won FDA approval for the 1st artificial pancreas . Continue reading >>

Medtronic Announces Voluntary Recall Of Diabetes Infusion Sets

Medtronic Announces Voluntary Recall Of Diabetes Infusion Sets

Medtronic Canada, a subsidiary of Medtronic plc (NYSE:MDT), announced today that Medtronic has started to inform patients worldwide of a voluntary recall of specific lots of infusion sets used with all models of Medtronic insulin pumps. The recall is related to a certain discontinued component in these infusion sets and does not include insulin pumps and glucose sensors. The company determined, through recent field reports from patients and root cause analysis, that a component, the vent membrane, in the recalled infusion sets may be susceptible to being blocked by fluid during the process of priming/fill-tubing. This situation can lead to potential over-delivery of insulin shortly after an infusion set change, which may cause hypoglycemia. Currently manufactured infusion sets, available to patients since April 2017, include a design update of this component which the company believes reduces the risk of insulin over-delivery after an infusion set change. The company will work with patients to ensure recalled infusion sets with the discontinued component are returned and replaced with new infusion sets containing the updated component at no cost. Medtronic has contacted the U.S. Food and Drug Administration (FDA), along with Health Canada and other regulatory bodies around the world, to share information related to this issue. Medtronic will continue working directly with government and regulatory authorities on this global voluntary recall. "Our priority is to work with our patients to mitigate risk to patient safety. While we have shipped a significant number of the new and enhanced sets since April, we are committed to replacing recalled infusion sets for all patients,” said Francine Kaufman, M.D., chief medical officer of the Diabetes Group at Medtronic “Our Med Continue reading >>

Medtronic Resource Centre Opens For Diabetic People In Canada

Medtronic Resource Centre Opens For Diabetic People In Canada

Medtronic Resource Centre Opens for Diabetic People in Canada June 14, 2017, 09:39:00 AM EDT By Zacks Equity Research, Zacks.com In order to drive its diabetes business, Medtronic plc MDT has ventured into the untapped market of Canada. The company announced that its subsidiary has opened its first Canadian Medtronic Resource Centre to serve diabetic patients in Surrey BC and nearby. Through this centre, Medtronic aims to provide extended services like education, support and other resources to local health care practitioners and their Type 1 or Type 2 Diabetes patients who depend on insulin pump and continuous glucose monitoring (CGM) technologies. This centre will provide post-marketing care to patients on an intensive insulin regiment using Medtronic insulin pump technology.Accordingly, management expects to raise the bar to a new level of support for patients with diabetes. Per management, this establishment will help diabetic patients reduce long-term complications related to this disease, which will further improve patients' lives. According to BCC Research , the global diabetes market should reach $155 billion by 2021, at a CAGR of 4.4% in the 2016 to 2021 period. Clearly, the company has bountiful opportunities in this niche market. Over the last three months, Medtronic has been lagging the Zacks categorized Medical Product industry.As per the last share price movement, the company has gained 4.7%, compared to the 5.61% gain of the broader industry. We expect positive developments like the recent investment plan in Canada to drive the company's share price. Medtronic recently launched MiniMed 670G system, a Hybrid Closed Loop insulin delivery system for Type I diabetic patients. This followed the U.S. FDA approval received late last year. MiniMed 670G should hel Continue reading >>

Tech Update: Medtronic (canada)

Tech Update: Medtronic (canada)

Reservoir Size: Can hold 300 units of Rapid-Acting Insulin Site Specifics: Works with Medtronics line of pump sites Quick-set, Silhouette, Mio, Mio 30, and Sure-T. Bolus Wizard: Built-in bolus calculator that considers active insulin, carbs and BG to help determine precise bolus amounts Colour Home Screen:Home screen shows active insulin, CGM reading (if using CGM) OR last BG readings entered in past 12 minutes, bolus and basal options Basal Patterns:Ability to save 8 basal patterns (think, sick day, aerobic workout day, travel day, time of the month day the list goes on!) Preset Bolus:You can save preset boluses. Do you always bolus the same for breakfast? Save that bolus in your pump for easy access Event Markers & Reminders:You can tag events on your pump to show up in your records exercise, feeling sick, stressed, etc. You can also have the pump send you reminders: Dont forget to set temp basal, check BG 2 hours after meal, etc. The enhanced Enlitewas released in Canada in 2014, a second version of the original Enlite sensor. There are several upgrades to this sensor from the original version, listed below. The enhanced Enlite is also the part of the 630G system that really makes this pump special: Sensor size: The actual part that is inside your body sensing is 80% smaller than previous Enlites Consistent:The new design allows more consistent reading over the wear of the sensor Connection:The wireless connection allows for better communicationbetween the sensor and the pump for fewer lost signal alarms Adhesive:The adhesive has been updated to cause less skin irritation SmartGuard Technology: This technology works to help prevent lows. When your BG drops below your set low threshold, it will suspend. The pump will stay suspended for 2 hours unless the user respond Continue reading >>

Largest Study Of Its Kind Shows Benefits Of Medtronic Insulin Pumps For People With Type 2 Diabetes

Largest Study Of Its Kind Shows Benefits Of Medtronic Insulin Pumps For People With Type 2 Diabetes

Largest Study of Its Kind Shows Benefits of Medtronic Insulin Pumps for People With Type 2 Diabetes Study With Canadian Roots Shows Insulin Pumps Safely Provided Significant, Sustainable and Reproducible Improvements in Glucose Control in Comparison to Multiple Daily Injections DUBLIN, IRELAND--(Marketwired - April 13, 2016) - Medtronic plc ( : MDT ), a global leader in medical technology, today announced the publication of new data in Diabetes, Obesity and Metabolism from the continuation phase of the OpT2mise study, providing further clinical evidence in support of the use of insulin pumps for people with insulin-requiring type 2 diabetes. The OpT2mise study is the largest randomized controlled trial to compare the efficacy and safety of insulin pump use versus multiple daily injections (MDI) for poorly controlled type 2 patients. One third of the 331 study participants were from Canada. Study findings showed that MiniMed® insulin pumps safely provided significant, sustainable and reproducible improvements in glucose control in comparison to MDI. At 12 months, the group that crossed over to MiniMed insulin pumps after an initial six months of MDI doubled their A1C reduction (a blood measurement used to indicate glucose control) from 0.4% to 0.8% while using 19% less insulin. "The continuation phase of OpT2mise builds on the findings of the initial study period, which showed that the use of insulin pumps helped participants with insulin-requiring type 2 diabetes safely achieve better glucose control, with lower insulin doses, than MDI," said Ronnie Aronson MD, FRCPC, FACE, lead author of the continuation phase of the study and executive director at LMC Diabetes & Endocrinology in Toronto, Ontario, Canada. "We found that participants who switched from MDI to insulin Continue reading >>

Increased Demand Leads To Global Shortage Of Diabetes Equipment Component

Increased Demand Leads To Global Shortage Of Diabetes Equipment Component

Increased demand leads to global shortage of diabetes equipment component Increased demand leads to global shortage of diabetes equipment component A global shortage of a component used in conjunction with a popular brand of insulin pump has left some people resorting to older methods to test their blood sugar. Company working 'around the clock' to meet increased demand Posted: Aug 25, 2017 3:08 PM AT | Last Updated: August 25, 2017 Insulin pumps work by delivering insulin 24 hours a day through a catheter placed under the skin, giving Type 1 and Type 2 diabetes patients a little more flexibility in their routine compared with traditional injection methods. (The Associated Press) A global shortage of a component used in conjunction with a popular brand of insulin pump has left some people resorting to older methods to test their blood sugar. Medtronic, a Dublin-based medical technology development company, said a global surge in demand for their glucose sensor has lead to a "temporary disruption" in supply. "This shouldn't happen," said Mark Merrett of Dartmouth, N.S. "They should have saw it coming." The 37-year-old was diagnosed with Type 1 diabetes at 16. He has been using an insulin pump for over 10 years and the continuous glucose monitors (CGMs) for four or five years. Medtronic says it's working around the clock to meet demand for the sensors. (Associated Press) Insulin pumps work by delivering insulin 24 hours a day through a catheter placed under the skin, giving Type 1 and Type 2 diabetes patients a little more flexibility in their routine compared with traditional injection methods. The devices know how much insulin to release and how often because of a tiny electrode sensor placed below the skin that continuously measures the amount of glucose in the blood. Continue reading >>

More in diabetes